XNK broadens its pipeline with bladder cancer study
XNK Therapeutics AB (“XNK”) today announced it is initiating a program targeting urothelial cancer, the most common form of bladder cancer. This is the first project where XNK’s proprietary technology platform of natural killer (NK) cell therapies is applied towards solid tumors. The company will collaborate with the Karolinska University Hospital in Solna, Sweden.“XNK is in a strong financial position and the time is right to continue to broaden our pipeline beyond hematological malignancies. Urothelial bladder cancer is a severe disease with large unmet medical need,” said Johan Liwing,